Umeå based ecotech company Boreal Orchards has signed an agreement with a major Canadian mining company to deploy its proprietary re:moss technology across multiple Canadian mine sites, marking Boreal Orchards’ first large-scale commercial project in North America.
Swedish biotech company Omnio AB has raised an oversubscribed round of €2.9 million from existing investors and shareholders to advance its plasminogen-based therapy for hard-to-heal chronic wounds toward clinical studies. The new funding follows a €4.3 million financing round completed in spring 2025 and will support key development activities ahead of clinical trial applications.
MucoShield AB has joined Umeå Biotech Incubator (UBI) to advance the development of a new locally administered treatment designed to protect the oral mucosa during chemotherapy and prevent severe chemotherapy-induced oral mucositis (CIOM), one of the most painful and debilitating side effects by patients undergoing cancer treatment
“Our goal is to improve oral health in patients with impaired mucosal protection, regardless of whether the underlying cause is cancer therapy, medication, autoimmune disease, or ageing,” says Jean Lycke, Project Lead at MucoShield.
Umeå Biotech Incubator (UBI) has appointed Ingela Bergqvist as its new Lab and Community Manager. Holding a PhD in Cell and Molecular Biology and bringing nearly 20 years of experience in drug development, she will oversee UBI’s laboratory facilities and help strengthen support for the region’s life science companies and innovators.
Mucocort, a UBI-supported company, has published an article in Scientia Global. The article highlights the company’s Close-to-Market innovation strategy and how existing compounds can be transformed into new therapies through its 4R framework: Repurposing, Reformulation, Repositioning and Re-patenting.
Lipum, an UBI alumni, has signed the grant agreement for BEYOND, a project selected by Horizon Europe under the call Boosting the translation of biotech research into innovative health therapies. The project has been awarded approximately EUR 8 million, of which EUR 5.5 million will be allocated to Lipum.
Stockholm-based Agteria Biotech, a fast-growing agritech company, is expanding its presence in Umeå by moving into the laboratory facilities at Umeå Biotech Incubator (UBI). The company’s Research Technician, Madeleine Hollander, will be based on-site, providing Agteria with expanded research capacity.
“UBI’s lab capabilities will play a major role in our development,” says Madeleine Hollander.
Medicvent has secured two major hospital contracts in Sweden and France, with a combined value of approximately SEK 16 million. The awards follow a year of 11 percent revenue growth and mark an important step in the company’s international expansion.
“These contracts provide both an immediate financial contribution and highly valuable reference projects for our continued growth”, says Roger Folkhage, CEO of the Umeå-based company.
Construction of the facility in Umeå began in 2021. Diamyd Medical has now received GMP (Good Manufacturing Practice) certification and a manufacturing authorization from the Swedish Medical Products Agency for the production of biological investigational medicinal products.
“With this approval, the facility can play an important role for both Umeå and Sweden’s preparedness in a changing geopolitical landscape,” says Sofia Mayans, Head of Manufacturing Site in Umeå.
Umeå Biotech Incubator (UBI) has recruited Ololade Awoyomi to a new bridging role designed to accelerate the transition of life science projects from Umeå University’s Innovation Office into incubation at UBI.
Mucocort AB has received a patent in the United States for its innovative mucoadhesive patch technology, M045A, developed for the treatment of recurrent aphthous stomatitis (mouth ulcers). The approval marks a major milestone for the company and represents an important validation of its proprietary technology platform.
The Umeå Lab Fair sold out in record time this year. On May 7, 21 exhibiting companies will take part in Northern Sweden’s only dedicated life science lab fair.
“The strong interest is clear proof that we are meeting a real need, both among exhibitors and visitors,” says Christin Grundström, Lab and Community Manager at Umeå Biotech Incubator (UBI).
Umeå-based Nil Medical AB was awarded the Patient’s Award 2026 for its Nil Medical Vestpack at the MedTech4Health Innovation Award. The Patient’s Award recognizes the innovation judged to make the greatest difference for patients, users, and citizens.
Collaborations between academia and industry play an important role in turning research into practical applications. Researcher Chinmay Dwibedi shared insights from his work with BioGaia AB during the recent Open up for Innovation event at Umeå University.
SpinChem’s rotating bed reactor (RBR) technology is already deployed in more than 40 countries. Strengthened by the new EU–India Free Trade Agreement, the company is now expanding its presence in one of the world’s fastest-growing pharmaceutical markets through a partnership with Smart Labtech Private Ltd.
Umeå‑based Direkttest specializes in digital self‑sampling solutions, and continues its upward trajectory after its pandemic breakthrough. With a major new Swedish research contract secured and active discussions about expanding into the United Arab Emirates, the firm is now taking decisive steps toward both national and international growth.
The UBI company Nil Medical AB has been selected as a finalist in this year’s Medtech4Health Innovation Award for the Vestpack, a solution designed to make everyday life easier for children and young people undergoing medical treatment.
SpinChem AB has been certified according to ISO 9001:2015 by RISE, covering the company’s development, production, and delivery of rotating bed reactor (RBR) systems for advanced fluid processing.
Boreal Orchards is taking the next step in ecosystem restoration. With support from Vinnova (Sweden’s Innovation Agency) and industry partners, the company will develop methods to restore reindeer lichen in disturbed mining landscapes. The four-year project, ”symbios”, is funded with a total of SEK 15.5 million and brings together eight partners – including a Canadian mining company and the Swedish Sami Association.
Diamyd Medical has expanded its manufacturing strategy through a long‑term collaboration with APL in Umeå and a strategic partnership with NorthX Biologics, a contract development and manufacturing organisation (CDMO) based in Matfors, Sweden. Together, the parties will further develop and scale up production of the biological drug candidate retogatein (rhGAD65) in preparation for potential future commercialisation.